Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Memantine.

Blair Jarvis1, David P Figgitt

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.com

Drugs & Aging
|April 25, 2003
PubMed
Summary
This summary is machine-generated.

Memantine, a medication for Alzheimer's disease, slowed deterioration in patients with moderate to severe Alzheimer's disease. It also improved dementia measures in some patients, showing potential benefits for cognitive function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.

Drugs·2006
Same author

Cyberball: a program for use in research on interpersonal ostracism and acceptance.

Behavior research methods·2006
Same author

Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.

PharmacoEconomics·2005
Same author

Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence.

CNS drugs·2005
Same author

Pregabalin: as adjunctive treatment of partial seizures.

CNS drugs·2005
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Geriatrics

Background:

  • Alzheimer's disease and vascular dementia are progressive neurodegenerative disorders.
  • Current treatments offer limited efficacy, necessitating novel therapeutic approaches.
  • NMDA receptor antagonists represent a potential therapeutic target.

Purpose of the Study:

  • To evaluate the efficacy and safety of memantine in patients with Alzheimer's disease and vascular dementia.
  • To assess the impact of memantine on cognitive function, global impression of change, and behavioral symptoms.

Main Methods:

  • Randomized, double-blind, placebo-controlled, multicenter trials were conducted.
  • Patients received either memantine (10 mg/day or 20 mg/day) or placebo.
  • Standardized scales including the Alzheimer's Disease Assessment Scale and the Behavioral Rating Scale for Geriatric Patients were used.

Related Experiment Videos

Main Results:

  • Memantine 20 mg/day significantly slowed deterioration in outpatients with moderate to severe Alzheimer's disease over 28 weeks.
  • Memantine 10 mg/day improved dementia measures in care-dependent inpatients with Alzheimer's disease or vascular dementia over 12 weeks.
  • Responders were significantly more frequent in memantine groups based on Clinical Global Impression of Change and specific behavioral subscales.

Conclusions:

  • Memantine demonstrates efficacy in slowing disease progression and improving symptoms in patients with Alzheimer's disease and vascular dementia.
  • The drug appears to be generally well-tolerated, with common adverse events including diarrhea, insomnia, dizziness, headache, and hallucinations.
  • Further research may explore optimal dosing and long-term effects in diverse dementia populations.